Friday, June 16, 2017

Mavrilimumab at the 2017 EULAR Annual Meeting in Madrid

I’ve written quite a few times about mavrilimumab on this blog. The blogpost on “Mavrilimumab at the EULAR 2012” [1] attracted about 9000 visitors. And I’ve also written about mavrilimumab in Chinese [2]. So I might say that I’m interested in mavrilimumab.

Mavrilimumab is a human granulocyte-macrophage colony-stimulating factor receptor-α (GM–CSFR-α) monoclonal antibody. At the 2017 EULAR Annual Meeting we’ve only seen one study.

G. Burmester and colleagues presented [3]: “RESULTS OF A LONGITUDINAL REVIEW OF PULMONARY FUNCTION AND SAFETY DATA IN A PHASE IIB CLINICAL PROGRAMME TESTING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM–CSF) RECEPTOR ANTAGONIST MAVRILIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS (RA)”. The authors concluded: “We believe this is the most comprehensive longitudinal study of pulmonary function in a clinical RA programme.” O.K., but other seems to do fine without the need to such testing. And after 5 long years we’re still in phase 2b. The authors also concluded: “… its acceptable safety profile advocates initiation of Phase III studies with mavrilimumab. Further studies are now required to fully characterise pulmonary function over time in RA.” Further studies on pulmonary function!

My opinion in 2012: “this doesn't seem to be the start of a success story”. Clinical Trials lists 6 studies on mavrilimumab, which are completed or have been terminated [4]. In German we have the word “dümpeln”, which means “to bob up and down” or “to stagnate”. Mavrilimumab dümpels. But maybe the sponsor will initiate a phase 3 study.

Links and References:
[3] Annals of the Rheumatic Diseases, volume 76, supplement 2, year 2017, page 564 / Session: Rheumatoid arthritis - other biologic treatment , (Poster Presentations ) / DOI: 10.1136/annrheumdis-2017-eular.3131


No comments:

Post a Comment